Patient general characteristics
| Patient group . | N . | Sex . | Median age, y (range) . | Presentation* . | Post-IS† . | Response to IS . | SCT (median days from diagnosis to SCT) . |
|---|---|---|---|---|---|---|---|
| AA | 93 | 52F/41M | 42 (5-80) | 33 | 75‡ | 63% (47/75) | 4 (100) |
| hMDS | 24 | 8F/16M | 60 (16-83) | 23 | 3 | 33% (1/3) | 5 (174) |
| Patient group . | N . | Sex . | Median age, y (range) . | Presentation* . | Post-IS† . | Response to IS . | SCT (median days from diagnosis to SCT) . |
|---|---|---|---|---|---|---|---|
| AA | 93 | 52F/41M | 42 (5-80) | 33 | 75‡ | 63% (47/75) | 4 (100) |
| hMDS | 24 | 8F/16M | 60 (16-83) | 23 | 3 | 33% (1/3) | 5 (174) |
IS indicates immunosuppressive therapy; SCT, stem cell transplant; F, female; M, male; AA, aplastic anemia; SNP-A, single nucleotide polymorphism array; and hMDS, hypocellular myelodysplastic syndrome.
Patients with sample at presentation.
Patients with sample post-IS (52 samples available for SNP-A analysis).
Eleven patients had samples pre- and post-IS.